Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Drug-coated Balloons short
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 53s
Watch time: 4m 57s
Watch time: 8m 2s
Watch time: 3m 25s
Watch time: 4m 43s
Watch time: 4m 14s
Watch time: 7m 48s
Watch time: 7m 44s
Watch time: 10m 34s
Watch time: 9m 40s
Articles
Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era
Citation:
European Cardiology Review 2017;12(2):89–91
- Views:
357
- Downloads:
0
Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy
Citation:
European Cardiology Review 2017;12(2):88
- Views:
332
- Downloads:
0
Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker
Citation:
European Cardiology Review 2017;12(2):96.
- Views:
95
- Downloads:
0
Dual Anti-platelet Therapy after Coronary Stenting: Rationale for Personalized Duration of Therapy
Citation:
US Cardiology Review 2017;11(1):31–6
- Views:
3887
- Downloads:
0